Intervening Effect of Promoting Lung and Resolving Phlegm Method on Mouse Model Combining Disease and Syndrome of Human Coronavirus Pneumonia with Cold-dampness Pestilence Attacking Lung
10.13422/j.cnki.syfjx.20201149
- VernacularTitle:宣肺化痰法对冠状病毒肺炎寒湿疫毒袭肺小鼠病证结合模型的干预作用
- Author:
Rong-hua ZHAO
1
;
Jing SUN
1
;
Yu-jing SHI
1
;
Lei BAO
1
;
Zi-han GENG
1
;
Shan-shan GUO
1
;
Yan-yan BAO
1
;
Ying-jie GAO
1
;
Wen XIA
2
;
Tian-tian SUN
2
;
Liang-kun SUN
2
;
Xing LI
2
;
Xiao-lan CUI
1
Author Information
1. Biosecurity Laboratory, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
2. Guizhou Bailing Enterprise Group Pharmaceutical Co. Ltd, Anshun 550000, China
- Publication Type:Research Article
- Keywords:
novel coronavirus pneumonia (COVID-19);
method of promoting lung and resolving phlegm;
mouse model combining disease and syndrome of human coronavirus pneumonia with cold-dampness pestilence attacking lung;
Kesuting syrups;
Keqing capsules;
inflammatory factors;
immune cells in peripheral blood
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(11):21-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the therapeutic effect of Kesuting syrups and Keqing capsules, which have the function of promoting lung and resolving phlegm, on a mouse model combining disease and syndrome of human coronavirus pneumonia with cold-dampness pestilence attacking lung. Method:The therapeutic effects of Kesuting syrups (the doses of 22, 11 mL·kg-1) and Keqing capsules (the doses of 1.155, 0.577 5 g·kg-1) on this model were evaluated by the inflammatory changes of lung tissue, the expression of viral nucleic acid, the contents of inflammatory factors [interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)-α and interferon-γ (IFN-γ)], and the percentages of immune cells in peripheral blood (CD4+ T cells, CD8+ T cells and B cells). Result:Compared with the model group, high- and low-dose groups of Keqing capsules and Kesuting syrups could significantly reduce the inflammatory damage in the lung tissues of mice, Keqing capsules could significantly increase the percentages of CD4+ T cells, CD8+ T cells and B cells in peripheral blood, Keqing capsules and Kesuting syrups could reduce the expression levels of IL-6, IL-10, TNF-α and IFN-γ, inhibit the viral load in lung tissue, as well as improve the pathogenic manifestations of lung tissue. Conclusion:As the first-line drugs for novel coronavirus pneumonia, Keqing capsules and Kesuting syrups have significant therapeutic effect on the mouse model combining disease and syndrome of human coronavirus pneumonia with cold-dampness pestilence attacking lung, and the mechanism may be related to regulating immune function and reducing cytokine storm.
